Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 6/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15299885 | 0.91 | MEN1 (0.47) | MEN1TSHRKMT2ARENCAPN1 | |
| SCHEMBL21458028 | 0.84 | REN (0.49) | RENCAPN1PSMB1 | |
| SCHEMBL3840760 | 0.84 | REN (0.49) | RENCAPN1PSMB1 | |
| SCHEMBL21458081 | 0.80 | CAPN1 (0.66) | RENCAPN1PSMB1 | |
| SCHEMBL21458079 | 0.80 | CAPN1 (0.66) | RENCAPN1PSMB1 | |
| SCHEMBL4401138 | 0.80 | CAPN1 (0.66) | RENCAPN1PSMB1 | |
| SCHEMBL21457988 | 0.78 | CAPN1 (0.64) | MEN1TSHRKMT2ACAPN1 | |
| SCHEMBL28028172 | 0.78 | MEN1 (0.41) | MEN1TSHRKMT2ARENCAPN1 | |
| SCHEMBL3842569 | 0.77 | CTSK (0.52) | KMT2AMETAP2 | |
| SCHEMBL30128799 | 0.76 | CTSK (0.47) | RENCAPN1PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | MEN1 2693/4885TSHR 992/4885KMT2A 2235/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | MEN1 2693/4885TSHR 992/4885KMT2A 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.